LenioBio

LenioBio

Private
DusseldorfHealthcare & Life Scienceshttps://leniobio.com

Last Round

Grant

Jul 23, 2025

Total Funding Raised

$11.88M

Company Overview

LenioBio is a biotechnology company that provides a cell-free protein expression platform, ALiCE®, designed to accelerate the discovery, development, and scalable production of complex proteins for the biopharmaceutical industry.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

cell-free protein synthesisCFPSprotein expression platformdifficult-to-express proteinsprotein synthesis kitsprotein expression serviceCRO servicesplant-based protein expressiondrug discoverybiomanufacturingin vitro protein synthesisscalable protein productionhigh-throughput expressionHTPEantibody screeningmembrane protein expressionvaccine development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LenioBio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

LenioBio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantJul 23, 2025
GrantFeb 8, 2024
GrantMay 9, 2022
GrantAug 22, 2019

Key People

Founding team and executive leadership

Andre Goerke

Chief Executive Officer

Executive Team

Hugh Watson

Chief Financial Officer

Executive Team

Sabine Imamoglu

Chief Operating Officer

Executive Team

LenioBio Investors

Notable investors and investment history

InvestorRounds
CEPIGrant
European CommissionGrant
EU4Health ProgrammeGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 3, 2025

    Partnered with AffinityAI for AI-driven protein design.

  • Jul 23, 2025

    Secured $4.35M in grant funding.

LenioBio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

LenioBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about LenioBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersDusseldorf
Employee Range52
Year Founded2016
Last FundingJul 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.